New semantics in GoPubMed and European biotech start-ups

Transinsight has announced the launch of GoPubMed.com version 4.0, the semantic search engine for the life sciences with significantly improved features.
  • Increased Speed: GoPubMed 4.0 is ten times faster than its predecessor, now handling millions of documents in seconds.
  • Intelligent search: Never miss a document. The new interactive filtering process reduces millions of documents to a handful of key papers in just a few clicks. The Web 2.0 query processing helps by suggesting search ideas as you type.
  • More document sources: The GoPubMed.com website offers searches on PubMed and the Web at no cost. The professional version of GoPubMed PRO is designed to include intranet searches and patents.
  • Improve GoPubMed: The public website GoPubMed.com allows users to manually annotate and verify papers including their background information. The platform has already about 60.000 enthusiastic helping hands. GoPubMed shows the semantic path to the future: community generated ontologies and so improves the quality of search results.

"GoPubMed PRO for corporate semantic searches can handle multiple ontologies represented in many languages. The integrated semi-automated ontology generation tool helps to create ontologies of unknown domains much faster than doing them by hand. Local intranet and desktop searches will help our customers extend the power of the semantic search technology to their local information pools which helps reduce the time needed for manual information retrieval significantly. Cutting down the average hours spent weekly (12.4) on information searches to a little more than 1 hour can be directly expressed in terms money spent." explains Dr. Liliana Barrio-Alvers, CTO at Transinsight. "This is what our customers appreciate: greater efficiency that translates into faster and higher returns on their investments."

The judges of the European Venture Summit, which took place 1 & 2 December 2008 in Düsseldorf, Germany, ranked Transinsight and GoPubMed PRO as one of the Top 5 presenters in Biotech.

GoPubMed builds on cutting edge research developed in cooperation with TU Dresden in the EU project Sealife and is supported by INNO-WATT. For more information go to: www.GoPubMed.com.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honored with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...